Anacetrapib is a potent, selective, reversible rhCETP and mutant CETP (C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure.

Evacetrapib is a potent and selective inhibitor of CETP with IC50 of 5.5 nM.

CKD-519 is a selective and potent cholesteryl ester transfer protein (CETP) inhibitor being developed for the treatment of dyslipidemia to raise high-density lipoprotein cholesterol.

Torcetrapib is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma.

BMS 795311 is a potent cholesteryl ester transfer protein (CETP) inhibitor with IC50 of 4 nM.

Dalcetrapib is a rhCETP inhibitor with IC50 of 0.2 μM.